Bardoxolone (CDDO)

Bardoxolone (CDDO) is an activator of NRF2 used in studies of Apoptosis and Oxidative Stress Response. It is especially relevant when investigators need a named chemical input and interpretable readouts connected to caspase-associated cell-death signaling and survival decisions and redox signaling, ROS handling, and antioxidant defenses in apoptosis, cancer, and immunology models.

By activating NRF2, Bardoxolone (CDDO) can be used to examine caspase-associated cell-death signaling and survival decisions and redox signaling, ROS handling, and antioxidant defenses. The signaling pathway modulator annotation adds relevance to pathway-reporter and mechanistic-phenotyping studies, together with downstream-response mapping in the same experimental setting. In apoptosis, cancer, and immunology models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving NRF2
• Pathway perturbation studies connected to Apoptosis and Oxidative Stress Response
• Gain-of-function pathway-activation studies
• Pathway-reporter and mechanistic-phenotyping studies

Overall, Bardoxolone (CDDO) is appropriate when a defined chemical perturbant is needed to connect NRF2 with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in apoptosis, cancer, and immunology models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.